Correspondance with management thread, page-58

Zelda Therapeutics Ltd (ASX:ZLD) continues to progress its core clinical and pre-clinical activities focused on medicinal cannabis.

Importantly, it has also established the foundations to commercialise its medicinal cannabis products in the event the clinical programs are successful.

Zelda remains on-track to report on the outcome from its clinical trials for insomnia, autism and opioid reduction by mid-2019.

The company is also continuing to assess opportunities to expand its clinical programs where they align with its strategic objectives.

Finally, Zelda is progressing discussions with third parties aiming at securing agreements to distribute clinically-validated Zelda products globally.